nafronyl has been researched along with Lung Diseases, Obstructive in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reiterer, W | 1 |
1 trial available for nafronyl and Lung Diseases, Obstructive
| Article | Year |
|---|---|
[Effects of naftidrofuryl (Dusodril) on central hemodynamics and respiration].
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Furans; He | 1975 |